



Company

6.0 5.0

4.0 3.0

2.0

1.0

0.0

Sep-24

Oct-24

BinDawood Holding Co.

2Q25 Result Review

Vov-24

Rating

Under Review

Bloomberg Ticker

May-25

BINDAWOO Avg. price, SAR (RHS)

Apr-25

Jun-25

Jul-25

BINDAWOO AB

Date

14 August 2025

Results

Target Price SAR	UR
Upside/ Downside	_

Current Market Price (SAR)	5.5
52wk High / Low (SAR)	8.1/5.4
12m Average Vol. (mn)	1.5
Mkt. Cap. (USD/SAR mn)	1,687/6,332
Shares Outstanding (mn)	1,143.0
Free Float (%)	26.5%
3M ADTV (SAR mn)	5.2
6M ADTV (SAR mn)	5.1
P/E'25e (x)	22.4
EV/EBITDA'25e (x)	9.1
Dividend Yield '25e (%)	3.6
Price Perf. (1m/3m) (%)	-10.4/-10.4

Research Department

Email: ubhar-research@u-capital.net

4.0 2.0 0.0 92-6ny

8.0

6.0

Pharma business supports revenue growth in 2Q25

Jan-25

Dec-24

Avg. Volume, mn (LHS)

BinDawood Holding's (BDH) revenue grew 4% YoY in 2Q25. Expansion of standalone retail pharmacies, following the acquisition of Zahrat Al Rawdah Pharmacies in 1Q25, as well as integration of pharmacy stores in existing Danube and BinDawood stores, aided the revenue growth. Additionally, the distribution business, which was acquired in 3Q24, and improved performance of Ykone in the Middle East and India, also helped in driving the top line higher.

Feb-25

Mar-25

Net profit declines sharply on increased operational costs

An expansion in margins of the pharma and distribution business and improved terms from suppliers in grocery retail boosted gross profit by 11% YoY. However, a 19% YoY rise in total operating expenses, partly due to additional costs arising from the pharma & distribution business, an increase in finance costs resulting from acquisitions, and reduced finance income, led to a 33% YoY dip in the net profit in 2Q25.

U-Capital view

We plan to revisit our investment case on BDH, considering its notably weaker-thanexpected 2Q25 earnings performance, and hence place the stock under review. For our last report



Financial Summary

	•											
SAR mn	2Q24	3Q24	4Q24	1Q25	2Q25	2Q25e	YoY	QoQ	Var.	1H24	1H25	YoY
P&L												
Revenue	1,418	1,361	1,426	1,674	1,474	1,575	4%	-12%	-6%	2,891	3,149	9%
Gross profit	480	450	513	529	533	543	11%	1%	-2%	931	1,062	14%
Operating profit	102	57	127	93	80	110	-21%	-13%	-27%	185	173	-6%
Net profit	75	35	110	66	50	81	-33%	-23%	-37%	136	116	-14%
BS												
Sh. Equity	1,471	1,440	1,399	1,357	1,493		2%	10%		1,471	1,493	2%
Ratios												
Gross margin	33.9%	33.0%	36.0%	31.6%	36.2%	34.5%				32.2%	33.7%	
Operating margin	7.2%	4.2%	8.9%	5.5%	5.5%	7.0%				6.4%	5.5%	
Net profit margin	5.3%	2.6%	7.7%	3.9%	3.4%	5.1%				4.7%	3.7%	
EPS, SAR	0.06	0.03	0.09	0.06	0.04	0.07				0.12	0.10	
RoE (TTM)					18.3%							
TTM P/E (x)					24.3							

Source: Financials, Tadawul, Bloomberg, U Capital Research



Investment Research

Ubhar-Research@u-capital.net

Head of Research

Tahir Abbas

🎨 +968 2494 9036 │ **₌⊠** tahir@u-capital.net

Research Team

Ahlam Al Harthi

🎨 +968 2494 9024 │ 🚉 ahlam.harthi@u-capital.net

Sandesh Shetty

Amira Al Alawi

Dua Al Mawali

Head of Brokerage

Talal Al Balushi

🎨 +968 2494 9051 │ **:**区 talal@u-capital.net

Visit us at www.u-capital.net





Disclaimer

Recommendation

BUY	ACCUMULATE	HOLD	REDUCE	SELL
Greater than 20%	Between +10% and +20%	Between +10% and -10%	Between -10% and -20%	Lower than -20%



Ubhar Capital SAOC (U Capital)

Website: www.u-capital.net

PO Box 1137, PC 111, Sultanate of Oman

Tel: +968 2494 9036 | **Fax:** +968 2494 9099 | **Email:** research@u-capital.net

Disclaimer: This report has been prepared by Ubhar Capital (U Capital) Research and is provided for information purposes only. Under no circumstances is it to be used or considered as an offer to sell or solicitation of any offer to buy. While all reasonable care has been taken to ensure that the information contained therein is not untrue or misleading at the time of publication, we make no representation as to its accuracy or completeness and it should not be relied upon as such. The company accepts no responsibility whatsoever for any direct or indirect consequential loss arising from any use of this report or its contents. All opinions and estimates included in this document constitute U Capital Research team's judgment as at the date of production of this report and are subject to change without notice. This report may not be reproduced, distributed or published by any recipient for any other purpose.